Zai Lab (ZLAB) – Biotech Growth & Profitability Path

Company Overview:
Zai Lab ZLAB , a leading Chinese biotech firm, is on track for non-GAAP profitability by Q4 2025, driven by strong revenue growth & cost management.

Key Catalysts:

Financial Discipline & Expansion 💰

Operating losses fell 45% in Q4 2024, highlighting cost efficiency while scaling operations.
Analysts project $2 billion in annual revenue by 2028, reinforcing long-term value creation.
Blockbuster Drug Pipeline 💊

VYVGART generated $93.6M in its first full launch year, demonstrating strong adoption.
KarXT & bemarituzumab are key upcoming growth drivers, expanding ZLAB’s market footprint.
Investment Outlook:
Bullish Case: We are bullish on ZLAB above $34.00-$35.00, supported by financial execution & product expansion.
Upside Potential: Our price target is $54.00-$55.00, driven by strong product adoption & long-term growth trajectory.

🔥 Zai Lab – Unlocking the Future of Biotech Innovation. #ZLAB #Biotech #GrowthStocks